Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan(Besremi)

[andrew_huang]

In addition to the indications for PV and ET, Besremi expects the phase 3 clinical success of the new coronavirus. Judging from the current coronavirus pandemic in about a few years,

This is good news for MPN patients. Usually, patients will have the problem of decreased immunity during treatment, and they are in a high-risk period.

link.springer.com/article/1...

[Bluetop]

Thanks for posting -positive news.